Analytical Data
-
基因名
GRINL1A
- Application
-
别名
MYZAP; MYOZAP; Myocardial zonula adherens protein; GRINL1A upstream protein; Gup
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P0CAP1
-
表达区间
1-368aa
-
氨基酸序列
MCSLPRGFEPQAPEDLAQRSLVELREMLKRQERLLRNEKFICKLPDKGKKIFDSFAKLKAAIAECEEVRRKSELFNPVSLDCKLRQKAIAEVDVGTDKAQNSDPILDTSSLVPGCSSVDNIKSSQTSQNQGLGRPTLEGDEETSEVEYTVNKGPASSNRDRVPPSSEASEHHPRHRVSSQAEDTSSSFDNLFIDRLQRITIADQGEQQSEENASTKNLTGLSSGTEKKPHYMEVLEMRAKNPVPQLRKFKTNVLPFRQNDSSSHCQKSGSPISSEERRRRDKQHLDDITAARLLPLHHMPTQLLSIEESLALQKQQKQNYEEMQAKLAAQKLAERLNIKMRSYNPEGESSGRYREVRDEDDDWSSDEF
-
分子量
68.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Recombinant Human FCGR2A Protein，His
Cat：PA1000-1102
Recombinant E.coli nirK Protein，His
Cat：PA2000-3942
Protein Description
GRINL1A, a member of the glutamate receptor ion channel family, has garnered significant attention in recent years due to its potential implications in neurodevelopmental and psychiatric disorders. As a repressor of glutamate signaling, GRINL1A is believed to play a critical role in synaptic plasticity and neuronal communication. Research has shown that aberrations in glutamate signaling pathways are linked to conditions such as schizophrenia, autism, and epilepsy, making GRINL1A a compelling target for therapeutic interventions. The study of GRINL1A recombinant proteins enables researchers to delve deeper into its structural and functional characteristics, providing insights into how it regulates glutamate receptor activity. By producing and characterizing this protein in vitro, scientists can explore its binding interactions, post-translational modifications, and impact on neuronal excitability. Furthermore, understanding GRINL1A's role in various signaling pathways could illuminate its contribution to developmental processes in the brain. This knowledge is essential for the development of targeted therapies aimed at restoring normal glutamate signaling in affected individuals, thus highlighting the importance of GRINL1A in both basic neuroscience research and potential clinical applications.
